Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
FAQs

What are Trends in ADC Development?

In the first generation of ADC drugs, anticancer drugs mainly bind to mouse monoclonal antibodies through non-degradable linkers.

 

In the second generation of ADC drugs, monoclonal antibodies are becoming more selective for tumor cells and less cross-reactive with normal cells. However, most second-generation ADCs currently show narrow therapeutic window due to off-target toxicity, competition with unbound antibodies, and ADC aggregation or rapid clearance due to a drug-to-antibody ratio (DAR) of 8.

 

The optimization of monoclonal antibody, linker and coupling process can improve the therapeutic index of third-generation ADC. Site-specific coupling is considered the key to the successful development of ADC, which ensures the definite DAR value and the homogeneity of ADCs.